Merck & Co – known as MSD outside the US and Canada – has received a recommendation from The National Institute for Health and Care Excellence (NICE) for its new injectable treatment, Keytruda, with chemotherapy in adults with a rare form of triple negative breast cancer.
It is estimated that around 100 people per year with triple negative breast cancer may benefit from the treatment.
Given as an injection every three weeks, the treatment specifically targets triple negative breast cancer. Keytruda, also called pembrolizumab, has been recommended for adults who have not had chemotherapy for metastatic disease, and where surgery to remove the tumour is impossible…
